KineMed, Organon explore new apps for discontinued drugs

KineMed and Organon announced today that they have signed an agreement to discover new applications for multiple drug candidates.

EMERYVILLE, Calif.—KineMed, Inc., a pathway-based drug discovery and development company, and Organon announced today that they have signed an agreement to discover new applications for mul­tiple drug candidates.
Under the agreement, KineMed will apply its proprietary technol­ogies, AquaTag and KineMarker, to find alternative applications for discontinued compounds for­merly in the clinical-stage pipeline of Organon, a manufacturer and marketer of prescription medications with its head offices split between Roseland, N.J., and Oss, The Netherlands.
Once therapeutic utility is estab­lished for a selected drug candi­date, KineMed and Organon will jointly determine a development and commercialization path, including a potential joint effort.
"Our focus at KineMed is to maximize the value of drug com­pounds, applying our technology to discover indications that would have otherwise gone undetected and thereby enabling new ave­nues for drug development and commercialization," says David Fineman, president and CEO of KineMed. "We are pleased to announce the collaboration with Organon, which is a significant demonstration of our ability to forge partnerships with health­care organizations that are leading the innovation of new therapies worldwide."
David Nicholson, executive VP of global research and development at Organon, adds, "We at Organon are dedicated to maximize the potential of R&D compounds. KineMed's ability to measure the outputs of complex pathways in in vivo studies may lead to the dis­covery of new indications and as such holds great promise."
KineMed is employing its proprie­tary biomarker technology to mea­sure the real-time activity of drugs in whole body systems. KineMed is developing therapeutics both on its own and with pharma collabo­rators, and its technology report­edly expedites the drug develop­ment process and has demonstrat­ed results in metabolic disorders, neurodegeneration, diseases of inflammation and cancer, among other conditions.
Organon, which sells products in more than 100 countires, oper­ates primarily in the core thera­peutic fields of fertility, gynecol­ogy, anesthesia and neuroscience, but also conducts research in such areas as immunology and oncol­ogy.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Front Cover

Latest Issue  

• Volume 18 • Issue 12 • December 2022/January 2023

December 2022/January 2023

December 2022/January 2023 issue